New Maturation Inhibitor Enters Phase 2 Testing

September 18, 2008

Vivecon (MPC-9055), a new maturation inhibitor, is moving into early Phase 2 studies. The experimental antiretroviral will be studied in HIV-positive people to determine the proper dose of the drug, according to a press release from Myriad Genetics.

Maturation inhibitors prevent HIV from properly assembling into infectious particles, which occurs at the end of the virus's life cycle.

Vivecon was tested in HIV-negative volunteers to assess its short-term safety and determine how well the body absorbs it. According to Myriad, Vivecon achieved therapeutic drug levels in the blood and did not cause significant side effects.

© 2026 Smart + Strong All Rights Reserved.
http://beta.docker.poz.com/article/hiv-maturation-vivecon-15292-7298